Jia-Xiang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jia-Xiang Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ling-Shuang Liu
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine. No. 725, South Wanping Road, Shanghai 200032, China
3 shared publications - Chunjie Li
Shanghai Clinical Medicine Centre of TCM Oncology, Tumor Department of Longhua Hospital affiliated to Shanghai University of TCM.
2 shared publications - Guangxin Ruan
Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
1 shared publication - Hegen Li
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication - HuiRu Guo
Department of Oncology, Longhua Hospital, Shanghai University of TCM, 725 Wanping road, Shanghai 200032, China
1 shared publication - JianLi Sun
Department of Oncology, Longhua Hospital, Shanghai University of TCM, 725 Wanping road, Shanghai 200032, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 112
Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients
Background: Traditional Chinese medicine (TCM) is a widely applied complementary therapy for cancer patients. It can reduce the chemical drugs induced toxic effects to improve the quality of life (QOL). This study applies the highest quality of clinical trial methodology to examine the role of TCM in improving QOL of postoperative non-small-cell lung cancer patients. Methods and design: This study is a multi-center, randomized, placebo-controlled, double-blind trial. Four hundred eighty patients will be recruited into seven different research centers in China. These patients that meet the inclusion criteria will be randomized into either a treatment group or a placebo group. Each group will receive treatments of 3-weekly chemotherapy with TCM or placebo for four cycles. The primary outcome will involve the evaluation of QOL and the secondary outcome assessments will include two-year disease-free survival rate and disease-free survival. Other efficacy assessments are changes of TCM symptoms and toxicity. Side effects and safety profile of the therapy would be evaluated at the same time. The investigators expect that TCM therapy combined with chemotherapy is superior to chemotherapy solely in terms of QOL improvement and disease-free survival extension. "Intention-to-treat" analysis will include all randomized participants. Discussion: The results from the clinical trial will provide evidence for the effectiveness of chemotherapy combined with or without TCM in QOL of postoperative NSCLC patients. Trial registration: Clinical Trials.gov (Identifier: NCT01441752).
- 1 August 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 112
Open AccessMulti-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients
Background: Traditional Chinese medicine (TCM) is a widely applied complementary therapy for cancer patients. It can reduce the chemical drugs induced toxic effects to improve the quality of life (QOL). This study applies the highest quality of clinical trial methodology to examine the role of TCM in improving QOL of postoperative non-small-cell lung cancer patients. Methods and design: This study is a multi-center, randomized, placebo-controlled, double-blind trial. Four hundred eighty patients will be recruited into seven different research centers in China. These patients that meet the inclusion criteria will be randomized into either a treatment group or a placebo group. Each group will receive treatments of 3-weekly chemotherapy with TCM or placebo for four cycles. The primary outcome will involve the evaluation of QOL and the secondary outcome assessments will include two-year disease-free survival rate and disease-free survival. Other efficacy assessments are changes of TCM symptoms and toxicity. Side effects and safety profile of the therapy would be evaluated at the same time. The investigators expect that TCM therapy combined with chemotherapy is superior to chemotherapy solely in terms of QOL improvement and disease-free survival extension. "Intention-to-treat" analysis will include all randomized participants. Discussion: The results from the clinical trial will provide evidence for the effectiveness of chemotherapy combined with or without TCM in QOL of postoperative NSCLC patients. Trial registration: Clinical Trials.gov (Identifier: NCT01441752).
- 1 January 2009
- Vol. 29 (1) , 26-9
[Regulatory effect of jianpi wenshen recipe in combining with chemotherapy on the blood level of estradiol in patients with lung cancer].
To observe the regulatory effect of Jianpi Wenshen Recipe (JPWS), a Chinese herbal preparation for strengthening Pi and warming Shen, combined with chemotherapy on the level of estradiol (E2) in patients with mid-late non-small cell lung cancer (NSCLC), and to analyse the relationship between the changes of estradiol and tumor size. Fifty-one NSCLC patients were randomized into three groups: 16 cases in the JPWS group treated with JPWS alone, 18 cases in the test group treated with combined therapy of JPWS plus chemotherapy, and 17 cases in the chemotherapy group treated with chemotherapy alone, all were treated for 2 months. The changes of blood E2 level and tumor size before and after treatment were compared. The disease control rate in the JPWS group and combined therapy group was 53.85% (7/13) and 80.00% (8/10), respectively, both were higher than that in the chemotherapy group (44.40%, 4/9), but the difference showed statistical insignificance (P > 0.05). E2 level was significantly lowered after treatment in the former two groups (all P < 0.05), and the change was in accordance with that of tumor size in 26 out of 31 patients (P < 0.01). JPWS combined with chemthherapy can stabilize the tumor size and down-regulate E2 levelo, with the change of E2 correlated with that of tumor size in patients. Hence, decreasing E2 is one of the mechanisms for JPWS in treating lung cancer.
- 1 January 2009
- Vol. 29 (1) , 26-9
[Regulatory effect of jianpi wenshen recipe in combining with chemotherapy on the blood level of estradiol in patients with lung cancer].
To observe the regulatory effect of Jianpi Wenshen Recipe (JPWS), a Chinese herbal preparation for strengthening Pi and warming Shen, combined with chemotherapy on the level of estradiol (E2) in patients with mid-late non-small cell lung cancer (NSCLC), and to analyse the relationship between the changes of estradiol and tumor size. Fifty-one NSCLC patients were randomized into three groups: 16 cases in the JPWS group treated with JPWS alone, 18 cases in the test group treated with combined therapy of JPWS plus chemotherapy, and 17 cases in the chemotherapy group treated with chemotherapy alone, all were treated for 2 months. The changes of blood E2 level and tumor size before and after treatment were compared. The disease control rate in the JPWS group and combined therapy group was 53.85% (7/13) and 80.00% (8/10), respectively, both were higher than that in the chemotherapy group (44.40%, 4/9), but the difference showed statistical insignificance (P > 0.05). E2 level was significantly lowered after treatment in the former two groups (all P < 0.05), and the change was in accordance with that of tumor size in 26 out of 31 patients (P < 0.01). JPWS combined with chemthherapy can stabilize the tumor size and down-regulate E2 levelo, with the change of E2 correlated with that of tumor size in patients. Hence, decreasing E2 is one of the mechanisms for JPWS in treating lung cancer.
- 20 December 2008
- Vol. 11 (6)
[Progress of traditional Chinese medicine and western treatment for elderly advanced lung cancer.].
- 20 December 2008
- Vol. 11 (6)
[Progress of traditional Chinese medicine and western treatment for elderly advanced lung cancer.].
- 1 April 2008
- Vol. 28 (4) , 352-5
[Clinical effect of yiqi yangyin jiedu decoction in treating patients with advanced non-small cell lung cancer].
To observe the clinical therapeutic effect and mechanism of Yiqi Yangyin Jiedu Decoction (YYJD, a Chinese herbal recipe for strengthening qi, nourishing yin and removing toxic substance, consisting of milkvetch root 30 g, glehnia root 30 g, asparagus root 15 g, lilyturf root 15 g, grossy privet fruit 12 g, spikemoss herb 30 g, Chinese sage herb 30 g, manyleaf paris rhizome 30 g, etc. ) in treating patients with advanced nonsmall cell lung cancer (NSCLC). Sixty patients with advanced lung cancer of qi-yin deficiency syndrome were randomized into three groups: the TCM group (A) treated with YYJD, the chemotherapy group (B) treated by chemotherapy with NP or GP protocol, and the combined treated group (C) treated with YYJD and chemotherapy in combination. The efficacy was evaluated after two cycles of treatment. The total effective rate for alleviating qi-yin deficiency syndrome in group A was 80%, significantly higher than that in Group C and B (35% and 20%, P <0.01) respectively. The KPS increasing and stabilizing rate in Group A and C was 90% and 85% respectively, significantly higher than that in Group B (75%), and difference between A and B was significant (P <0.05). In Group C after treatment, CD(3)+ showed a rising trend (P = 0.05), different to that in Group A and B (P <0.05 and P <0.01); CD(4)+ significantly increased (P <0.05) and CD(4)+/CD(8)+ ratio showed increasing trend (P = 0.06), while in Group B both were decreased significantly, showed significantly difference (P < 0.05). CD(8)+ CD(28)+ significantly increased after treatment in Group A and C (P <0.01 and P <0.05), but showed decreasing trend (P = 0.06) in Group B, significant difference was shown between B and C (P <0.05). YYJD can ameliorate the qi-yin deficiency syndrome evidently in advance lung cancer patients; improve their quality of life, the mechanism might be by way of enhancing T-lymphocyte activity and killer T-cell function, to elevate the T-cell mediated immunity in a round way.
- 1 April 2008
- Vol. 28 (4) , 352-5
[Clinical effect of yiqi yangyin jiedu decoction in treating patients with advanced non-small cell lung cancer].
To observe the clinical therapeutic effect and mechanism of Yiqi Yangyin Jiedu Decoction (YYJD, a Chinese herbal recipe for strengthening qi, nourishing yin and removing toxic substance, consisting of milkvetch root 30 g, glehnia root 30 g, asparagus root 15 g, lilyturf root 15 g, grossy privet fruit 12 g, spikemoss herb 30 g, Chinese sage herb 30 g, manyleaf paris rhizome 30 g, etc. ) in treating patients with advanced nonsmall cell lung cancer (NSCLC). Sixty patients with advanced lung cancer of qi-yin deficiency syndrome were randomized into three groups: the TCM group (A) treated with YYJD, the chemotherapy group (B) treated by chemotherapy with NP or GP protocol, and the combined treated group (C) treated with YYJD and chemotherapy in combination. The efficacy was evaluated after two cycles of treatment. The total effective rate for alleviating qi-yin deficiency syndrome in group A was 80%, significantly higher than that in Group C and B (35% and 20%, P <0.01) respectively. The KPS increasing and stabilizing rate in Group A and C was 90% and 85% respectively, significantly higher than that in Group B (75%), and difference between A and B was significant (P <0.05). In Group C after treatment, CD(3)+ showed a rising trend (P = 0.05), different to that in Group A and B (P <0.05 and P <0.01); CD(4)+ significantly increased (P <0.05) and CD(4)+/CD(8)+ ratio showed increasing trend (P = 0.06), while in Group B both were decreased significantly, showed significantly difference (P < 0.05). CD(8)+ CD(28)+ significantly increased after treatment in Group A and C (P <0.01 and P <0.05), but showed decreasing trend (P = 0.06) in Group B, significant difference was shown between B and C (P <0.05). YYJD can ameliorate the qi-yin deficiency syndrome evidently in advance lung cancer patients; improve their quality of life, the mechanism might be by way of enhancing T-lymphocyte activity and killer T-cell function, to elevate the T-cell mediated immunity in a round way.